Nantahala Capital Management LLC Has $13.56 Million Position in Codexis, Inc. (NASDAQ:CDXS)

Nantahala Capital Management LLC reduced its holdings in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,841,660 shares of the biotechnology company's stock after selling 126,148 shares during the period. Nantahala Capital Management LLC owned 3.49% of Codexis worth $13,555,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CDXS. Northern Trust Corp increased its position in shares of Codexis by 16.7% in the fourth quarter. Northern Trust Corp now owns 688,189 shares of the biotechnology company's stock valued at $3,283,000 after acquiring an additional 98,256 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in Codexis by 83.1% in the fourth quarter. Tudor Investment Corp ET AL now owns 106,365 shares of the biotechnology company's stock valued at $507,000 after purchasing an additional 48,272 shares in the last quarter. Empire Financial Management Company LLC increased its position in shares of Codexis by 21.1% during the 4th quarter. Empire Financial Management Company LLC now owns 270,000 shares of the biotechnology company's stock worth $1,288,000 after purchasing an additional 47,048 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Codexis by 38.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,552 shares of the biotechnology company's stock worth $151,000 after purchasing an additional 8,832 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Codexis by 162.4% in the 4th quarter. MetLife Investment Management LLC now owns 46,160 shares of the biotechnology company's stock valued at $220,000 after buying an additional 28,569 shares during the last quarter. 78.54% of the stock is owned by institutional investors.

Codexis Stock Up 8.6 %

CDXS traded up $0.20 during trading on Friday, reaching $2.52. 591,184 shares of the stock were exchanged, compared to its average volume of 660,360. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The stock's 50 day moving average price is $2.55 and its two-hundred day moving average price is $3.78. Codexis, Inc. has a twelve month low of $1.90 and a twelve month high of $6.08. The stock has a market cap of $208.75 million, a P/E ratio of -2.90 and a beta of 2.35.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The firm had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million. Equities analysts expect that Codexis, Inc. will post -0.77 EPS for the current year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.